| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
12,653,000 |
| Market
Cap: |
2.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.187 - $0.187 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Manzo Michael P. |
VP of Engineering |
• – – |
2021-08-03 |
4 |
D |
$2.40 |
$156 |
D/D |
(65) |
15,378 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-08-03 |
4 |
D |
$2.40 |
$151 |
D/D |
(63) |
15,321 |
|
- |
|
| Boyd Steven |
10% Owner |
– – • |
2021-08-02 |
4 |
S |
$2.40 |
$463,046 |
I/I |
(192,775) |
785,000 |
|
- |
|
| Boyd Steven |
10% Owner |
– – • |
2021-07-30 |
4 |
S |
$2.69 |
$183,562 |
I/I |
(68,188) |
977,775 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-07-29 |
4 |
S |
$3.00 |
$1,200,000 |
I/I |
(400,000) |
1,045,963 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-07-28 |
4 |
S |
$3.28 |
$1,232,617 |
I/I |
(375,443) |
1,445,963 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-07-27 |
4 |
S |
$3.80 |
$12,113,647 |
I/I |
(2,377,695) |
1,821,406 |
|
- |
|
| Boyd Steven |
Director |
– • • |
2021-07-27 |
4 |
OE |
$4.80 |
$4,092,000 |
I/I |
852,500 |
4,199,101 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-07-02 |
4 |
D |
$3.70 |
$3,245 |
D/D |
(877) |
69,305 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-07-02 |
4 |
D |
$3.70 |
$570 |
D/D |
(154) |
15,384 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-07-02 |
4 |
D |
$3.70 |
$592 |
D/D |
(160) |
15,443 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-07-02 |
4 |
D |
$3.70 |
$666 |
D/D |
(180) |
23,396 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-06-04 |
4 |
D |
$4.19 |
$649 |
D/D |
(155) |
15,603 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-06-04 |
4 |
D |
$4.19 |
$3,679 |
D/D |
(878) |
70,182 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-06-04 |
4 |
D |
$4.19 |
$754 |
D/D |
(180) |
23,576 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-06-04 |
4 |
D |
$4.19 |
$649 |
D/D |
(155) |
15,538 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-05-04 |
4 |
D |
$4.13 |
$789 |
D/D |
(191) |
15,693 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-05-04 |
4 |
D |
$4.13 |
$653 |
D/D |
(158) |
15,758 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-05-04 |
4 |
D |
$4.13 |
$3,672 |
D/D |
(889) |
71,060 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-05-04 |
4 |
D |
$4.13 |
$731 |
D/D |
(177) |
23,756 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-04-08 |
4 |
D |
$4.94 |
$4,441 |
D/D |
(899) |
71,949 |
|
- |
|
| Romano Sarah |
Chief Financial Officer |
• – – |
2021-04-08 |
4 |
D |
$4.94 |
$889 |
D/D |
(180) |
23,933 |
|
- |
|
| Mann Brenda |
VP of Research & Development |
• – – |
2021-04-08 |
4 |
D |
$4.94 |
$948 |
D/D |
(192) |
15,884 |
|
- |
|
| Manzo Michael P. |
VP of Engineering |
• – – |
2021-04-08 |
4 |
D |
$4.94 |
$958 |
D/D |
(194) |
15,916 |
|
- |
|
| From Stephen |
Executive Chairman |
• • – |
2021-03-03 |
4 |
D |
$5.46 |
$4,903 |
D/D |
(898) |
72,848 |
|
- |
|
289 Records found
|
|
Page 2 of 12 |
|
|
